专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130345280A1 Methods And Compositions Employing Bicifadine For Treating Disability Or Functional Impairment Associated With Acute Pain, Chronic Pain, Or Neuropathic Disorders 有权
标题翻译：用于治疗与急性疼痛，慢性疼痛或神经性疾病相关的残疾或功能性损害的二百里加的方法和组合
公开(公告)号：US20130345280A1
公开(公告)日：2013-12-26
申请号：US13907920
申请日：2013-06-02
申请人： Arnold S. Lippa , Warren Stern , Janet Codd , Brian Boland , Johnson Lim
发明人： Arnold S. Lippa , Warren Stern , Janet Codd , Brian Boland , Johnson Lim
IPC分类号： A61K9/20 , A61K31/403
CPC分类号： A61K31/403 , A61K9/2054
摘要： Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.
摘要翻译：提供方法和组合物用于配制和施用二化蓖苷和相关化合物以治疗或预防与急性疼痛，慢性疼痛和神经性疾病相关的功能障碍和残疾。

2. 发明申请

US20080234354A1 Methods And Compositions For Controlling Body Weight And Appetite 审中-公开
标题翻译：用于控制体重和食欲的方法和组合
公开(公告)号：US20080234354A1
公开(公告)日：2008-09-25
申请号：US11943552
申请日：2007-11-20
申请人： Arnold S. LIPPA , Joseph W. Epstein , Joseph T. Tizzano , Anthony Basile
发明人： Arnold S. LIPPA , Joseph W. Epstein , Joseph T. Tizzano , Anthony Basile
IPC分类号： A61K31/403 , A61P3/04 , A61P3/10
CPC分类号： A61K31/40 , A61K31/403 , A61K45/06 , C07D209/52 , A61K2300/00
摘要： The present invention provides novel compositions and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound. The invention also provides novel compositions and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease, osteoarthritis, osteoporosis, dislipidemias, gout, atherosclerosis, joint pain, sexual and fertility problems, respiratory problems, gall bladder disease, skin conditions, hypertension, diabetes, stroke, pulmonary embolism, sleep apnea, idiopathic intracranial hypertension, lower extremity venous stasis disease, gastro-esophageal reflux, urinary stress incontinence, metabolic syndrome, insulin resistance and cancer. The methods and compositions of the invention may employ a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound alone, or in combination with a second anti-appetite or anti-obesity agent.
摘要翻译：本发明提供了使用（+）-1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷或相关化合物来控制食欲和体重和/或治疗肥胖症的新型组合物和方法。本发明还提供了用于治疗或预防与体重过重或肥胖相关或复杂的疾病的新型组合物和方法，包括冠心病，骨关节炎，骨质疏松症，血脂异常，痛风，动脉粥样硬化，关节疼痛，性和生殖问题，呼吸问题，胆囊疾病，皮肤病，高血压，糖尿病，中风，肺栓塞，睡眠呼吸暂停，特发性颅内高压，下肢静脉淤滞疾病，胃食管反流，尿失禁，代谢综合征，胰岛素抵抗和癌症。本发明的方法和组合物可以单独使用（+）-1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷或相关化合物，或与第二抗食欲或抗 - 肥胖剂。

3. 发明授权

US6162463A Extended release formulation of diltiazem hydrochloride 失效
标题翻译：盐酸地尔硫卓的缓释制剂
公开(公告)号：US6162463A
公开(公告)日：2000-12-19
申请号：US67573
申请日：1998-04-28
申请人： Arnold S. Lippa
发明人： Arnold S. Lippa
IPC分类号： A61K9/00 , A61K9/50 , A61K9/52 , A61K31/00 , A61K31/55 , A61K31/554 , A61P9/00 , A61K9/48
CPC分类号： A61K9/5084 , A61K31/554
摘要： An extended release formulation of diltiazem which is suitable for once-daily oral administration comprises a quantity of a quick release preparation of diltiazem or a pharmaceutically active salt thereof, mixed with a quantity of a slow release (or delayed release) preparation of diltiazem or a pharmaceutically active salt thereof. The quick release preparation used obtains a maximal release of diltiazem within approximately 1-2 hours after administration, and then falls toward baseline levels. The delayed release preparation individually shows a maximal release of diltiazem at between approximately 6-8 hours after administration. The formulation containing the two preparation achieves a maximal release of diltiazem approximately within 1-2 hours after administration, and the levels of released diltiazem remain near these maximal levels for approximately another 12 hours after administration, compared to other extended release formulations of diltiazem (referred to herein as slow or delayed release preparations) which achieve maximal release approximately 9 hours after oral administration. The preferred embodiment is a capsule containing the formulation, which, based upon the total quantity of drug in the formulation rather than total weight of the formulation, comprises up to approximately 25 percent by weight of the quick release preparation of diltiazem, and up to 75 percent by weight of the slow (or delayed) release preparation of diltiazem. The present invention has application for combinations of other preparations of quick release and slow or delayed release pharmaceuticals.
摘要翻译：适用于每日一次口服给药的地尔硫卓的延长释放制剂包含一定数量的地尔硫卓快速释放制剂或其药物活性盐，与一定量的缓释（或延迟释放）制剂的地尔硫卓或其药物活性盐。所用的快速释放制剂在施用后约1-2小时内可以获得地尔硫卓的最大释放，然后降至基线水平。缓释制剂在施用后约6-8小时分别显示地尔硫卓的最大释放。含有两种制剂的制剂在给药后1-2小时内达到最大限度地释放地尔硫卓，与其他延缓释放的地尔硫卓配方相比，给药后释放的地尔硫卓水平在给药后约12小时保持接近这些最大水平在本文中作为缓释或延迟释放制剂），其在口服给药后约9小时达到最大释放。优选的实施方案是含有制剂的胶囊，其基于制剂中药物的总量而不是制剂的总重量，包含高达约25重量％的地尔硫卓快速释放制剂，最多75 缓慢（或延迟）地尔硫卓释放制剂的重量百分比。本发明适用于快速释放和缓释或延迟释放药物的其它制剂的组合。

4. 发明授权

US06377693B1 Tinnitus masking using ultrasonic signals 失效
标题翻译：使用超声波信号进行耳鸣屏蔽
公开(公告)号：US06377693B1
公开(公告)日：2002-04-23
申请号：US08264527
申请日：1994-06-23
申请人： Arnold S. Lippa , James A. Nunley
发明人： Arnold S. Lippa , James A. Nunley
IPC分类号： A61F1106
CPC分类号： A61F11/045 , A61N2007/0026
摘要： A method and apparatus for treating tinnitus involves generating a noise signal to mask the ringing or buzzing in the ears caused by tinnitus and transposing the noise signal into the ultrasonic frequency range. As such, the masking signal effectively masks the tinnitus noise without interfering with the subject's perception of normal sounds such as human speech. In an alternative embodiment, human speech is transduced into electrical signals, transposed to the ultrasonic frequency range, and physically applied to the patient while tinnitus masking signals in the auditory range are applied to the patient.
摘要翻译：一种用于治疗耳鸣的方法和装置包括产生噪声信号以掩蔽由耳鸣引起的耳鸣的振铃或嗡嗡声，并将噪声信号转换到超声波频率范围内。因此，掩蔽信号有效地掩盖耳鸣噪声，而不会干扰对象对诸如人类语音的正常声音的感知。在替代实施例中，人类语音被转换成电信号，转置到超声波频率范围，并且物理地应用于患者，同时将听觉范围中的耳鸣屏蔽信号应用于患者。

5. 发明授权

US06173062B2 Frequency transpositional hearing aid with digital and single sideband modulation 失效
标题翻译：频率转换助听器，具有数字和单边带调制
公开(公告)号：US06173062B2
公开(公告)日：2001-01-09
申请号：US08214169
申请日：1994-03-16
申请人： Farid Dibachi , Charles S. Richardson , Arnold S. Lippa
发明人： Farid Dibachi , Charles S. Richardson , Arnold S. Lippa
IPC分类号： H04R2500
CPC分类号： H04R25/353 , H04R25/505
摘要： Apparatus and method for shifting the frequency range of an audio frequency range signal using digital frequency shifting and single sideband amplitude modulation techniques. In one embodiment, a frequency shifted single sideband, amplitude modulated signal is formed for application to the human hearing sensory system to provide enhanced hearing for hearing impaired persons. In another embodiment, the audio signal is shifted to an ultrasonic frequency range utilizing digital signal processing techniques in which an audio frequency signal is frequency shifted by modulation to a carrier frequency and in which a single sideband modulated signal is formed. The digital single sideband amplitude modulation techniques of this embodiment are also applicable to digital modulation systems for uses other than in hearing aids. In another embodiment, analog single sideband modulation is utilized for frequency shifting in a hearing aid application.
摘要翻译：使用数字频移和单边带幅度调制技术来移动音频范围信号的频率范围的装置和方法。在一个实施例中，形成了频移单边带幅度调制信号，以应用于人类听觉系统，以为听障人士提供增强的听力。在另一个实施例中，利用数字信号处理技术将音频信号转换到超声波频率范围，其中音频信号通过调制频移到载波频率，并且其中形成单个边带调制信号。本实施例的数字单边带幅度调制技术也适用于除助听器以外的用途的数字调制系统。在另一个实施例中，模拟单边带调制被用于助听器应用中的频移。

6. 发明公开

US20240100023A1 Compositions and Methods For Treating Spinal Cord Injuries 审中-公开
公开(公告)号：US20240100023A1
公开(公告)日：2024-03-28
申请号：US18388587
申请日：2023-11-10
申请人： Arnold S. LIPPA
发明人： Arnold S. LIPPA
IPC分类号： A61K31/4245 , A61K31/5377 , A61P25/28
CPC分类号： A61K31/4245 , A61K31/5377 , A61P25/28
摘要： The present invention relates to ampakines, including low impact ampakines, and pharmaceutical compositions and methods employing ampakines for treating central nervous system (CNS) disorders, including Spinal Cord Injuries. Novel compositions and methods are provided employing SCI recovery ampakines to treat attention deficit hyperactivity disorder (SCI) and related cognitive, behavioral and psychiatric conditions.

7. 发明授权

US06169813A Frequency transpositional hearing aid with single sideband modulation 失效
标题翻译：频带转移助听器，具有单边带调制
公开(公告)号：US06169813A
公开(公告)日：2001-01-02
申请号：US08212571
申请日：1994-03-16
申请人： Charles S. Richardson , Arnold S. Lippa
发明人： Charles S. Richardson , Arnold S. Lippa
IPC分类号： H04R2500
CPC分类号： H04R25/353 , H04R25/505 , H04R2225/43 , H04R2430/03
摘要： A hearing aid apparatus and method of the type in which audio frequency signals are frequency upshifted to ultrasonic frequency bands and are applied as vibrations to the human body to generate a hearing response. Frequency upshifting of the audio frequency signals to the ultrasonic frequency band is attained in one embodiment by amplitude modulation of an ultrasonic frequency carrier signal with an audio frequency modulating signal to form a modulated signal in which one of the two sidebands is either completely or substantially suppressed and a modulated signal having only one predominant sideband is thus derived for application to the human sensory system to generate a hearing response.
摘要翻译：一种助听器装置和方法，其中音频信号被频率升高到超声波频带，并作为振动施加到人体以产生听觉响应。在一个实施例中，通过对具有音频调制信号的超声频率载波信号的幅度调制来实现音频信号到超声波频带的频率升高，以形成其中两个边带之一完全或基本上被抑制的调制信号因此导出仅具有一个主导边带的调制信号，以应用于人感觉系统以产生听觉响应。

8. 发明授权

US4857514A Virus inactivation 失效
标题翻译：病毒灭活
公开(公告)号：US4857514A
公开(公告)日：1989-08-15
申请号：US776918
申请日：1985-09-17
申请人： Arnold S. Lippa , David I. Scheer
发明人： Arnold S. Lippa , David I. Scheer
IPC分类号： C12N7/04 , A61K20060101 , A61K31/685 , A61K39/00 , A61K39/21
CPC分类号： A61K31/685 , Y10S514/885 , Y10S514/934
摘要： A virus having a lipid-containing capsid, such as AIDS virus, is inactivated by contacting the virus with an inactivating amount of phosphatidyl choline. Such a virus can be inactivated in fluids such as virus-contaminated body fluids or derivatives, e.g., blood or blood derivatives. The phosphatidyl choline can be present in an Active Lipid (AL) composition further comprising neutral lipids and phosphatidyl ethanolamine. Phosphatidyl choline, and an AL composition containing same, is useful for the treatment or prophylaxis of Acquired Immune Deficiency Syndrome (AIDS) in mammals.
摘要翻译：通过使病毒与灭活量的磷脂酰胆碱接触，具有含脂质衣壳（例如AIDS病毒）的病毒被灭活。这种病毒可以在诸如病毒污染的体液或衍生物例如血液或血液衍生物的流体中灭活。磷脂酰胆碱可以存在于还包含中性脂质和磷脂酰乙醇胺的活性脂质（AL）组合物中。磷脂酰胆碱和含有它们的AL组合物可用于治疗或预防哺乳动物获得性免疫缺陷综合征（AIDS）。

9. 发明授权

US4777128A Fluorescence immunoassay involving energy transfer between two fluorophores 失效
标题翻译：荧光免疫测定涉及两个荧光团之间的能量转移
公开(公告)号：US4777128A
公开(公告)日：1988-10-11
申请号：US866952
申请日：1986-05-27
申请人： Arnold S. Lippa
发明人： Arnold S. Lippa
IPC分类号： G01N33/542 , G01N33/576 , G01N33/78 , G01N33/533
CPC分类号： G01N33/542 , G01N33/576 , G01N33/78 , Y10S436/80
摘要： In a fluorescence immunoassay system, first and second fluorophores are covalently bound to one of a member of a specific binding pair of liquid and receptor, the first of said fluorophores being capable of absorbing light at a first wavelength to produce light emission at a second wavelength, which second wavelength can be absorbed by the second fluorophore.
摘要翻译：在荧光免疫测定系统中，第一和第二荧光团共价结合于特异性结合对液体和受体的成员之一，所述第一荧光团能够吸收第一波长的光以产生第二波长的光，第二波长可被第二荧光团吸收。

10. 发明授权

US07098229B2 (+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof 有权
标题翻译：（+） - 1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷，其组成及用途
公开(公告)号：US07098229B2
公开(公告)日：2006-08-29
申请号：US10466457
申请日：2002-01-11
申请人： Arnold S. Lippa , Joseph W. Epstein
发明人： Arnold S. Lippa , Joseph W. Epstein
IPC分类号： A61K31/403 , C07D209/52
CPC分类号： C07D471/08 , A61K31/403 , A61K31/407 , A61K45/06 , C07D209/52 , A61K2300/00
摘要： The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (−)-enantiomer.
摘要翻译：本发明涉及（+） - 1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷及其药学上可接受的盐，其包含（+） - 1-（3,4-二氯苯基） 3-氮杂二环[3.1.0]己烷或其药学上可接受的盐，以及用于治疗或预防患者的抑郁症，焦虑障碍，进食障碍或尿失禁的复发的方法，包括给予（+） - 4-二氯苯基）-3-氮杂双环[3.1.0]己烷或其药学上可接受的盐。（+） - 1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷或其药学上可接受的盐优选基本上不含相应的（ - ） - 对映异构体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式